SCYX: צמיחת רווחי EPS רבעונית SCYNEXIS
SCYNEXIS, Inc. (SCYX) has minimized internal costs and created a royalty lever by transitioning to the licensing of antifungal agents to third-party tech giants. The quarterly relative change in EPS captures this effect, with the parameter mark equal to 48.20. Management stability is ensured by the partnership with GSK and revenue transparency, while the company simultaneously expands its antifungal product portfolio for the hospital and pharmacy sectors.
%20%D7%A6%D7%9E%D7%99%D7%97%D7%AA%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%9E%D7%95%D7%A0%D7%97%D7%99%D7%9D%20%D7%A9%D7%A0%D7%AA%D7%99%D7%99%D7%9D%20%D7%91%D7%A9%D7%A0%D7%99%D7%9D%20%D7%A2%D7%A9%D7%A8%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwa76aez.ocr-7cpmfb4&start=20220704&end=20261110&filename=GURU_Markets_-_SCYX_-_SCYNEXIS-Inc._-_Earnings-per-share-growth-in-annualized-terms-for-the-last-twelve-months "SCYNEXIS (SCYX): צמיחת רווחי EPS רבעונית מ-04.07.2022 עד 10.11.2026 | 👁️GURU.Markets👁️")
פילוחי נתונים אנליטיים מרוכזים עבור SCYNEXIS, Inc. (SCYX)
Quarterly EPS growth measures the rate of change in net income per share, allowing investors to assess capital generation efficiency over the short term. By analyzing quarterly EPS trends, one can compare market demand with actual returns, which for SCYNEXIS, Inc. (SCYX) depend directly on the stability of contract manufacturing for antifungal drugs and the continuity of their supply.
